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Development of secondary hyperparathyroidism and bone disease
in diabetic rats with renal failure
AQUILES JARA, J0RDI BOVER, and ARNOLD J. FELSENFELD
Department of Medicine, Wadsworth VA Medical Center and UCLA, Los Angeles, California, USA
The development of secondary hyperparathyroidism and bone disease
in diabetic rats with renal failure. Renal osteodystrophy in diabetic
patients on maintenance hemodialysis is characterized by a higher prev-
alence of low bone turnover and is associated with a relative deficiency of
parathyroid hormone (PTH) as compared with non-diabetic hemodialysis
patients. The goal of the study was to evaluate how diabetes affected the
development of secondary hyperparathyroidism (2° HPT) and bone
disease in azotemic rats. Three groups of 5/6 nephrectomized, pair-fed
male Wistar rats maintained on a high phosphorus (1.2%) diet were
studied: (1) the control group, non-diabetic azotemic rats (NDR); and two
streptozotocin-induced diabetic azotemic groups, (2) poorly-controlled
diabetic rats (PCDR) which received only enough NPH insulin to main-
tain the blood glucose between 300 and 400 mgldl, and (3) well-controlled
insulin-treated diabetic rats (IDR) which received a continuous insulin
infusion for 14 days via a subcutaneously implanted miniosmotic pump.
Serum calcium, phosphorus and creatinine levels were similar among the
three groups. Blood glucose levels were greater in the PCDR group than
the IDR and NDR groups (358 11 vs. 83 9 and 87 8 mg/dl,
respectively; P < 0.001). Rats in the PCDR group weighed less at sacrifice
as compared with the IDR and NDR groups (P < 0.05). Serum PTH levels
(normal 47 2 pg/ml) were elevated, but not different among the three
groups (136 34, 147 21 and 98 8 pg/mI in the PDCR, IDR and NOR
groups, respectively). The PCDR group as compared with the NDR and
IDR groups had a decreased osteoblast surface (9.0 1.8 vs. 26 4.1 and
24.6 4.1%, (P < 0.01), decreased osteoid surface (10.2 2.1 vs. 27.8
3.9 and 25.7 3.6%, P <0.01),decreased bone formation rate (0.11 .07
vs. 0.70 0.1 and 0.47 0.1 m3/jrm2/day, P < 0.01), and decreased
mineral apposition rate (1.27 0.5 vs. 2.99 0.2 and 2.89 0.2 piday, P
< 0.05). In summary, (1) a model of streptozotocin-induced diabetes in
surgically-induced azotemic rats was developed; (2) diabetes did not affect
the development of 2° HPT in this short-term study; (3) despite similar
elevations of serum PTH, poor control of diabetes resulted in a decreased
osteoblast surface and bone formation rate; (4) insulin administration and
normalization of blood glucose prevented the development of bone
abnormalities. Thus, in this experimental model of diabetes in azotemic
rats, the low bone turnover appeared to be a direct consequence of the
insulinopenic state rather than the result of decreased PTH levels.
Marked secondary hyperparathyroidism (2° HPT) is associated
with the bone disease, osteitis fibrosa, which is the most common
form of bone disease in patients on maintenance hemodialysis [1].
However, in diabetic patients on hemodialysis, the magnitude of
2° HPT is generally less than other dialysis patients and osteitis
fibrosa is uncommon [2—51. Furthermore, recent studies have
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shown that diabetic patients with renal failure tend to develop
adynamic bone disease [1, 6, 7], which is characterized by low
bone turnover and is associated with lower levels of parathyroid
hormone (PTH) than in hemodialysis patients with osteitis fibrosa
[81.
The reason for the adynamic bone disease and relative PTH
deficiency in the azotemic diabetic patient is not known. One
possibility is that these alterations are inherent to diabetes and
only become apparent in renal failure when the system is stressed.
However, several studies have suggested that mineral homeostasis
may be altered even in diabetic patients with normal renal
function. A decreased bone mass has been reported in several
studies of diabetic patients, especially in those with insulin
dependent diabetes [9—111. An increased incidence of hip, femo-
ral neck, and vertebral compression fractures have also been
observed [12—151. In bone histomorphometric studies of diabetic
patients, a decrease in bone turnover has been noted [4, 16].
Serum osteocalcin levels, a marker of osteoblast function [17],
have been reported to be decreased in experimental and human
diabetes [18—20]. However, it is difficult to know whether these
findings are due to a direct effect of diabetes on bone or a
consequence of hypoparathyroidism which has been reported in
some studies of diabetic patients with normal renal function
[21—23].
In previous animal studies of diabetes, PTH levels and bone
histology have been reported only in diabetic rats with normal
renal function [20, 24—30]. Results of PTH levels in these studies
have been contradictory inasmuch as a deficiency of PTH has
been reported in some [24—26], but not all studies [20, 28—301. It
has also been suggested that insulin may be an important factor
for normal PTH secretion [31]. Moreover, in an in vitro study of
parathyroid cells, high glucose concentrations suppressed the
PTH response to hypocalcemia and an insulin deficiency also
reduced PTH secretion [32].
In previous studies in the rat, we have shown that the surgical
induction of renal failure combined with a high phosphorus diet
markedly increased PTH levels and resulted in osteitis fibrosa [33,
34]. However, no information is available regarding the develop-
ment of 2° HPT and bone disease in diabetic rats with renal
failure. The purpose of this study was to determine whether: (1)
diabetes affected the development of 2° HPT and bone disease in
the diabetic rat with renal failure, and (2) correction of the insulin
deficiency and hyperglycemia in the diabetic rat with renal failure
negated any adverse effect of diabetes on the development of 2°
HPT and bone disease.
1746
Jara et al: Bone disease and PTH in the azotemic, diabetic rat 1747
Methods
Studies were performed with male Wistar rats weighing 140 to
160 grams at the time of selection for the study. The rats
designated to be rendered diabetic received a single injection of
streptozotocin (65 mg/kg) (Upjohn, Kalamazoo, MI, USA) into
the tail vein; the streptozotocin was freshly dissolved in pH 4.5
citrate buffer [24, 25, 35]. The control non-diabetic group received
normal saline. Establishment of diabetes was assessed five days
after streptozotocin administration and was considered to be
present if the blood glucose exceeded 300 mgldl. Five days after
streptozotocin administration, all rats including the non-diabetic
control group underwent arterial ligation of two of the three hilar
branches of the left main renal artery; this was followed one week
later by a right nephrectomy. During surgical procedures, rats
were anesthetized with ketamine 7.5 mg/100 g (Ketaset, Fort
Dodge Laboratories, Fort Dodge, IA, USA) and xylazine 0.5
mg/100 g (AnaSed, Lloyd Laboratories, Shenandoah, IA, USA)
administered intraperitoneally. Rats were housed in individual
cages and pair-fed. Each rat received 12 grams daily of a high
phosphorus diet (ICN Biomedicals, Cleveland, OH, USA) con-
taining 1.2% phosphorus, 0.6% calcium, and 100 IU of vitamin D
per 100 g of diet. This diet was used to induce phosphorus
retention and 2° HPT [33, 34]. All rats were allowed free access to
water.
The three study groups were (1) the control group, non-diabetic
azotemic rats (NDR); and two streptozotocin-induced diabetic
azotemic groups: (2) poorly-controlled diabetes rats (PCDR), and
(3) well-controlled insulin-treated diabetic rats (IDR). Immedi-
ately after the establishment of diabetes, the diabetic rats were
subdivided into the PCDR group and the IDR group. After the
arterial ligation of branches of the left main renal artery, both
groups received subcutaneous NPH insulin in doses adjusted daily
to maintain the blood glucose between 300 and 400 mg/dl in the
PCDR group, and between 100 and 200 mg/dl in the IDR group.
Seven days later, a right nephrectomy was performed; subse-
quently, the IDR group received regular insulin (U-500 Iletin II,
Eli Lilly & Co, Indianapolis, IN, USA) at a constant rate of 0.042
U/hr for 14 days via a subcutaneously implanted miniosmotic
pump (Aizet, model 2002, Alza, Palo Alto, CA, USA). To avoid
insulin aggregation in the Aizet pump, the insulin solution was
prepared according to the method described by Bringer, Heldt
and Grodsky [36]. Briefly, insulin was diluted with a solution of
1.6% glycerine and 0.2% phenol. L-glutamic acid was added to
the insulin solution to attain a concentration of 7 mg/mi; the pH
was then adjusted to 3.4 with NaOH and HCI. Before the
miniosmotic pump was filled, the insulin solution was passed
through a sterile 0.2 I.tm filter (Minisart SM 16534, Sartorius Co,
Long Island, NY, USA) to prevent bacterial contamination. Rats
in the PCDR group continued to receive daily subcutaneous NPH
insulin at a dose which maintained the blood glucose between 300
and 400 mg/dl. Preliminary studies showed that the failure to
maintain the blood glucose at less 400 mg/dl resulted in marked
polyuria, profound wasting, and death. Blood glucose was moni-
tored daily during the first week, and then every two days by
obtaining blood from the tail vein and measuring glucose with a
blood glucose meter (Glucoscan 3000, Lifescan mc, Mountain
View, CA, USA).
Eight rats were assigned to the non-diabetic azotemic group
(NDR) and 35 rats were assigned to receive streptozotocin with
the anticipation that diabetes may not develop in all the rats and
problems would develop in diabetic rats with renal failure. Of the
35 rats assigned to receive streptozotocin, six rats were excluded
because diabetes did not develop or they resolved spontaneously;
two rats were excluded because despite receiving an Aizet pump
containing insulin, blood glucose levels were consistently greater
than 200 mg/di; and an additional 14 rats died suddenly during the
study—five rats died before the right nephrectomy was per-
formed, six rats died after the right nephrectomy and inclusion in
the PCDR group, and three rats died after the right nephrectomy
and inclusion in the IDR group; the latter three deaths were
believed to be due to hypoglycemia. Thus, at the time of sacrifice,
the number of rats in the PCDR, IDR, and NDR groups were
seven, six, and eight, respectively.
Ten days and three days before sacrifice, all rats received an
intraperitoneal injection of tetracycline hydrochloride (20 mg) to
label the bone for histomorphometric studies. Fourteen days after
the right nephrectomy, rats were fasted overnight and the follow-
ing morning were anesthetized and sacrificed by exsanguination
from the abdominal aorta. The ilium was removed and processed
for bone histomorphometric analysis as described previously [37].
Briefly, 5- Goldner-stained sections of cancelious bone were
examined for cellular detail, osteoid, and mineralized bone; lO-t
unstained sections were analyzed for tetracycline labels. Quanti-
fication was performed at a magnification X 400 with a Merz-
Schenk reticle and 100 fields were counted. The recommendations
of the American Society for Bone and Mineral Research for bone
histomorphometric nomenclature [38] were followed. The defini-
tions for bone parameters evaluated included: (1) osteoblast
surface, the percentage of trabecular surface covered by osteo-
blasts; (2) osteoid surface, the percentage of trabecular surface
covered by osteoid; (3) quiescent surface, the percentage of
trabecular surface resting or inactive; (4) osteoclast surface, the
percentage of trabecular surface covered by osteoclasts; (5)
osteoclasts number/mm2, the number of osteoclasts per square
millimeter of cancellous bone; (6) osteoid volume, the percentage
of trabecular bone volume occupied by osteoid; (7) bone volume,
the percentage of cancellous bone occupied by trabecular bone;
(8) fibrosis volume, the percentage of cancellous bone occupied by
fibrosis; (9) double labeled surface, the percentage of trabecular
bone surface with double tetracycline label; (10) the bone forma-
tion rate was obtained by multiplying the double-labeled tetracy-
cline surface times the mineral apposition rate; (11) the adjusted
apposition rate was obtained by multiplying the mineral apposi-
tion rate times the mineralization surface (double-labeled tetra-
cycline surface) divided by the osteoid surface; (12) the mineral
apposition rate was obtained by measuring the distance between
the two tetracycline labels and dividing by the number of days
between tetracycline doses. As in previous studies [39, 40], only
the double-labeled tetracycline surface was used for the calcula-
tion of the bone formation rate because single tetracycline labels
were present to a considerably greater extent than the osteoid and
osteoblast surface combined.
Serum calcium was measured by atomic absorption (Perkin
Elmer, Norwalk, CT, USA); serum phosphorus with a specific kit
(Sigma Diagnostics, St. Louis, MO, USA); and serum creatinine
with a creatinine analyzer (Beckman Instruments, Fullerton, CA,
USA). Serum PTH was determined using an amino-terminal
radioimmunoassay (INS, Nichols Institute, San Juan Capistrano,
CA, USA); this assay has been validated previously for the
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Serum 0.9 0.2 0.8 0.1 0.9 0.1 0.25 0.01
creatinine,
mg/dl
Serum calcium, 8.7 0.3 8.6 0.4 8.8 0.3 9.9 0.1
mg/dl
Serum 9.8 1.4 10.8 1.4 10.0 0.8 7.6 0.2
phosphorus,
mgldl
PTH,pg/ml 136±34 147±21 98±8 47±2
Blood glucose, 358 11 83 9 87 8C
mgldl
Weight, grams' 159 7 197 7" 216 6" 208 0.5
N 7 6 8
Data are mean SE; N number of rats. Abbreviations are: PCDR
group, poorly controlled diabetic rats; IDR group, insulin-treated diabetic
rats; NDR group, non-diabetic rats.
P < 0.001 vs. PCDR groupbP < 0.05 vs. PCDR group
C Weight of rats at sacrificed Data from 66 male Wistar rats with normal renal function receiving
the same high phosphorus diet as the other groups [34] are provided for
comparison but were not included in the statistical analysis.
determination of circulating PTH in the rat [33, 34]. All PTH
measurements were performed in a single assay and the intraassay
coefficient of variation was 5.8%. A 24 hour urine was collected
prior to sacrifice, the urinary volume and creatinine were mea-
sured, and a creatinine clearance calculated.
Statistics
Since the data were not normally distributed, non-parametric
tests were used. For comparisons among three groups, the
Kruskal-Wallis test was used followed by the Connover's multiple
comparison test for the comparison between two groups. Results
are expressed as the mean standard error (sem) and a P value
<0.05 was considered to be significant.
Results
Serum calcium, phosphorus and creatinine levels were similar
among the three groups (Table 1). As compared with rats with
normal renal function on a high phosphorus diet [341, serum
calcium levels were lower and serum phosphorus levels were
higher in the three azotemic study groups. As designed, the
surgical induction of renal failure increased serum creatinine in
the study groups. The creatinine clearances were not significantly
different for the PCDR, IDR, and NDR groups, 2.38 0.39, 2.97
0.54, and 1.91 0.21 mi/mm/kg, respectively. This contrasts
with a creatinine clearance of 10.20 0.41 ml/min/kg in 26 normal
rats.
As shown in Figure 1, blood glucose levels were markedly
greater in the PCDR than the other two groups (P < 0.001) and
the blood glucose level was similar in the diabetic group receiving
a continuous insulin infusion (IDR group) and the non-diabetic
group (NDR group) (Fig. 1A). Serum PTH levels at sacrifice were
not different among the three groups (Fig. 1B).
As shown in Table 2 and Figure 2, the osteoblast surface and
osteoid surface were decreased (P < 0.005) in the PCDR group as
compared with the diabetic group receiving a continuous infusion
of insulin (IDR) and the non-diabetic group (NDR). However,
there were no differences in the osteoclast surface and osteoclasts/
mm2 among the three groups. The bone formation rate and the
mineral apposition rate were also decreased (P < 0.02) in the
poorly controlled diabetic group. There were no differences in any
bone parameter between the non-diabetic group and the diabetic
group with normal blood glucose levels.
Discussion
In this study, a model of diabetes mellitus was developed in rats
with surgically-induced renal failure. Two groups of diabetic,
azotemic rats were evaluated; in one group, diabetes was poorly
controlled and resulted in marked hyperglycemia and in the other
group, the administration of a continuous infusion of insulin
through a subcutaneously implanted miniosmotic pump resulted
in excellent control of the blood glucose. As expected, the
combination of renal failure and a high phosphorus diet in
non-diabetic rats produced an elevation of PTH levels; however,
diabetes did not affect the development of 2° HPT. Despite
similar PTH levels, poor control of the diabetes resulted in a
marked reduction of the osteoblast surface and bone formation
rate. Conversely, diabetic rats with normalization of the blood
glucose did not differ from their non-diabetic counterparts.
In our preliminary studies in diabetic rats with surgically-
induced renal failure, blood glucose exceeding 400 mgldl resulted
in marked polyuria, profound wasting, and death. Thus, it was
necessary to administer small doses of insulin to the poorly-
controlled diabetes group to maintain the blood glucose between
300 and 400 mg/dl. Despite these measures, the attrition rate was
high in the diabetic groups. All groups received the same amount
of an identical diet; however, the poorly-controlled diabetic group
lost weight. It was decided not to restrict calories in the other two
groups of rats because then the degree of phosphorus loading to
enhance the development of 2° HPT would be different among
the groups. Moreover, the weight loss in the poorly-controlled
diabetic rats was similar to published results in other studies in
diabetic rats [20, 24, 25] and in essence may be unavoidable in this
type of study.
In in vitro studies of parathyroid cells both hyperglycemia and
an insulin deficiency have been reported to have a direct suppres-
sive effect on PTH secretion [32]. Whereas there has been a
controversy about whether diabetes results in hypoparathyroidism
in diabetic patients with normal renal function [22], several
studies have noted a relative hypoparathyroidism in the majority
of diabetic patients on maintenance hemodialysis [1, 6, 7]. More-
over, dynamic testing of parathyroid function performed in dia-
betic hemodialysis patients have demonstrated a decreased PTH
response to hypocalcemia as compared with non-diabetic patients
on hemodialysis [8]. In the present study of diabetic, azotemic
rats, both hyperglycemic and euglycemic diabetic rats attained
similar elevated PTH levels as non-diabetic rats. Moreover, since
a similar degree of hypocalcemia and hyperphosphatemia was
present among the three groups, it is unlikely that these factors
varied the PTH levels at the time of sacrifice. Furthermore, the
magnitude of 2° HPT was not different in the poorly-controlled
diabetes group despite weight loss. Thus, in this short-term study,
diabetes did not affect the development of 2° HPT. Nevertheless,
these results do not eliminate the possibility that in a longer study,
diabetes could affect the secretory activity of parathyroid glands.
Another consideration is that diabetes-induced vascular disease of
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Fig. 1. Blood glucose and serum PTH levels in
diabetic and non-diabetic azotemic rats. Shown
are the blood glucose (A) and serum PTH
levels (B) in the poorly controlled diabetic
group (PCDR); the well-controlled insulin
treated diabetic group (IDR); and the non-
diabetic group (NDR). *p < 0.001 vs PCDR.











Osteoblast surface 9.0 1.8 24.6 4.P 26.0 4.1 15.8 3.3
(%)
Osteoid surface 10.2 2.1 25.7 3.6a 27.8 39C 18.6 2.9
(%)
Quiescent surface 76.2 3.2 55.3 60b 55.0 5.5" 70.6 3.4
(%)
Osteoclast surface 10.7 2.0 12.1 1.6 11.9 1.9 8.2 0.8
(%)
Osteoclasts/mm2 3.04 0.6 3.09 0.6 2.57 0.4 1.35 0.2
Osteoid volume 0.91 0.05 2.83 0.5 3.35 1.5 1.60 0.6
(%)
Bone volume (%) 13.3 1.6 11.1 2.0 12.1 21.2 7.4 1.2
Fibrosis volume (%) 0.23 0.08 0.88 0.3 0.30 0.1 0.07 0.05
Dynamic
measurements
Double labeled 3.7 2.5 15.7 2.8a 23.0 39C 11.1 0.9
surface (%)
Bone formation 0.11 0.07 0.47 0.1" 0.70 0.1" 0.20 0.01
rate (p.m3/p.m2/
day)
Adjusted apposition 0.72 0.4 1.94 0.5 3.02 09b 1.48 0.9
rate (it/day)
Mineral apposition 1.27 0.5 2.89 0.2" 2.99 0.2" 1.80 0.1
rate (jr/day)
Data are mean sn. Abbreviations are: PCDR group, poorly-con-
trolled diabetic rats; IDR group, insulin-treated diabetic rats; NDR group,
non-diabetic rats.
ap < 0.01 vs. PCDR group
"P < 0.05 vs. PCDR group
Data from 6 male Wistar rats with normal renal function receiving the
same high phosphorus diet as the other groups are provided for compar-
ison but were not included in the statistical analysis.
hypoparathyroidism observed in diabetic hemodialysis patients.
Diabetic patients requiring maintenance dialysis have had diabe-
tes for many years and in general, have extensive vascular disease.
In one study in a limited number of patients, parathyroid glands
obtained at parathyroidectomy from diabetic patients on hemo-
dialysis were reported to have intense fibrosis [41], and this was
interpreted to be a possible consequence of diabetic vascular
disease. However, detailed pathology of the parathyroid gland is
lacking in this group of patients.
Despite similar elevations of PTH, the poorly controlled dia-
betic group had a decreased osteoblast surface and bone forma-
tion rate. These bone histomorphometric findings were similar to
those previously reported in rats with normal renal function with
experimental (streptozotocin-induced) or spontaneous diabetes
(diabetic BB/W) [20, 24, 25, 42, 43]. These studies reported a
decreased osteoblast surface and a marked decrease in the bone
formation rate. These skeletal changes have been reported to be
a consequence of diabetes and, at least in vitro, were not related
to any specific effect of streptozotocin on bone [44]. Our results in
well-controlled diabetic rats would support the contention that
streptozotocin does not have a direct effect on bone. It has been
reported that serum from diabetic rats directly inhibits collagen
production [45]. Brenner et a! studied the effect of serum from
insulin-dependent diabetic children on normal human osteoblasts
in vitro, and reported that collagen synthesis was significantly
reduced when these cells were exposed to serum from diabetic
patients with marked hyperglycemia with HbAIC levels of 9%;
however, when euglycemia with a HbA1C level of 4.2% was
achieved, collagen synthesis was no longer inhibited [46].
In the present study it is possible that the weight loss in the
poorly-controlled diabetic group was responsible or contributed
to the observed differences in bone parameters. However, it
should be noted that not all bone parameters were decreased
since the osteoclast surface, osteoclasts/mm2 and endosteal fibro-
sis were similar among the three groups. Moreover, whereas a
marked decrease in osteoclasts has been observed in starvation
[47], a decrease in osteoclasts was not observed in other studies of
experimental diabetes [27]. Furthermore, in another study it was
reported that spontaneously diabetic BB rats had a severe reduc-
tion in the osteoblast surface and serum osteocalcin levels while
non-diabetic semistarved rats with the same weight as the diabetic
rats had a normal osteoblast and osteoid surface and normal
serum osteocalcin levels [42].
A decrease in the serum levels of osteocalcin, a marker of
osteoblast activity, has been reported in studies of diabetic rats
[20]. It has been postulated that the reduced serum osteocalcin
levels may be due to a lack of insulin, local growth factors such as
IGF-1, and/or a resistance to the action of 1,25-(OH)2D [43].
Verhaeghe et al have reported decreased plasma levels of IGF-1
and osteocalcin in spontaneously diabetic BB rats; histomorpho-
metric analysis of these rats showed a decreased osteoblast
surface, osteoid surface and mineral apposition rate. Insulin
infusion normalized osteoblast and osteoid surfaces and the
serum osteocalcin concentration; however, the mineral apposition
rate remained decreased. Conversely, an infusion of rhIGF-1
improved the mineral apposition rate, but had no effect on the
osteoblast surface and osteocalcin levels [431.
Results from a recent study suggest that hyperglycemia may not
influence the osteoblast activity. In this study, cyclosporine A was
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Fig. 2. Static and dynamic bone
histomorphometric measurements in diabetic and
non-diabetic, azotemic rats. Shown are the
osteoblast (A) and osteoclast (B) surface, the
bone formation rate (C), and the mineral
apposition rate (D) in the poorly controlled
diabetic group (PCDR); the well-controlled
insulin-treated diabetic group (IDR); and the
non-diabetic group (NDR). *p < 0.05 vs.
PCDR.
two groups of streptozotocin-induced diabetic rats [481. In non-
diabetic rats treated with cyclosporine, blood glucose levels in-
creased to approximately 350 mg/dl, which were similar to the
diabetic groups. While diabetic rats and diabetic rats receiving
cyclosporine had decreased osteocalcin levels, non-diabetic rats
which received cyclosporine had normal osteocalcin levels despite
a similar degree of hyperglycemia as the diabetic groups. Further-
more, both diabetic groups had a decreased bone formation rate
as compared with control and cyclosporine-treated non-diabetic
rats [48]. Thus, hyperglycemia did not appear to contribute to the
decreased osteoblast function and bone remodeling.
The precise role of insulin and whether an insulin deficiency is
a major factor in the abnormal bone pathology remains to be
determined. In an in vitro study with UMR 106—01 cells, an
osteosarcoma cell line with many characteristics of rat osteoblasts
[49], the addition of insulin to cells continuously exposed to PTH
resulted in a marked increase in thymidine incorporation [50].
Thus, during hyperparathyroidism in vivo, insulin interacting with
PTH may be an important factor for osteoblast proliferation. One
possible interpretation of these data is that the presence of
increased insulin levels would indicate the recent ingestion of food
and the presence of sufficient quantities of proteins which would
be necessary for the synthesis of new bone.
In summary, a model of diabetes in rats with surgically-induced
renal failure was developed. Diabetes did not affect the develop-
ment of 2° HPT in this short-term study. Despite similar PTH
levels, poor control of diabetes resulted in a decreased osteoblast
surface and bone formation rate. Insulin administration and
normalization of blood glucose prevented the development of
bone abnormalities. Thus, the low bone turnover observed in our
experimental model of diabetes in azotemic rats appeared to be a
direct consequence of the insulinopenic state rather than the
result of decreased PTH levels. Consequently, it is possible in the
diabetic patient on hemodialysis that the adynamic bone may
develop independent of the relative hypoparathyroidism. How-
ever, this does not eliminate the possibility that the relative
hypoparathyroidism is an important modifying factor.
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